Prospective Single Center Trial to Compare 68Ga-PSMA-11 and Axumin PET/CT (18F-Fluciclovine) for Restaging Prostate Cancer Patients With Biochemical Recurrence After Radical Prostatectomy
Phase of Trial: Phase II
Latest Information Update: 26 Jun 2019
Price : $35 *
At a glance
- Drugs Fluciclovine 18F (Primary) ; Gallium 68 PSMA (Primary)
- Indications Prostate cancer
- Focus Diagnostic use
- 21 Jun 2019 Status changed from active, no longer recruiting to completed.
- 04 Jun 2019 Results (n=50) presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 19 Apr 2019 Planned End Date changed from 2 Mar 2020 to 2 Mar 2021.